Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
673.70
-58.07 (-7.94%)
Apr 29, 2026, 1:57 PM EDT - Market open
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $3.61B in the quarter ending March 31, 2026, with 19.04% growth. This brings the company's revenue in the last twelve months to $14.92B, up 5.92% year-over-year. In the year 2025, Regeneron Pharmaceuticals had annual revenue of $14.34B with 0.99% growth.
Revenue (ttm)
$14.92B
Revenue Growth
+5.92%
P/S Ratio
4.60
Revenue / Employee
$968,177
Employees
15,410
Market Cap
68.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 14.34B | 140.90M | 0.99% |
| Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
| Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
| Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
| Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vertex Pharmaceuticals | 12.00B |
| Incyte | 5.36B |
| BeOne Medicines AG | 5.34B |
| argenx SE | 4.24B |
| Alnylam Pharmaceuticals | 3.71B |
| BioNTech SE | 3.37B |
| Royalty Pharma | 2.38B |
| Moderna | 1.94B |
REGN News
- 5 hours ago - Regeneron Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 6 hours ago - Regeneron beats quarterly results estimates on strong Dupixent demand - Reuters
- 7 hours ago - Regeneron Reports First Quarter 2026 Financial and Operating Results - GlobeNewsWire
- 4 days ago - Regeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing loss - CNBC
- 5 days ago - Regeneron Strikes Deal With Trump Administration To Cut Drug Prices - Benzinga
- 5 days ago - Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S. - GlobeNewsWire
- 5 days ago - Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free - CNBC
- 5 days ago - Regeneron to offer prescriptions at most favored nation prices, Trump says - Reuters